度洛西汀和氟西汀治疗癌症抑郁患者的随机对照研究  

Randomized controlled study of duloxetine and fluoxetine in cancer patients with depression

作　　者：程素满 陈金峰[2] 许萍 

机构地区：[1]开封市第五人民医院,河南开封475003 [2]开封大学化学工程学院,河南开封475004

出　　处：《中国新药与临床杂志》2011年第4期266-268,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的探讨度洛西汀治疗癌症抑郁患者的临床疗效。方法采用前瞻性随机开放试验方法,将60例癌症抑郁患者分为度洛西汀和氟西汀组各30例,观察治疗6wk。于治疗前及治疗1、2、4、6 wk末采用汉密尔顿抑郁量表(HAMD)和焦虑量表(HAMA)评定疗效,用副反应量表(TESS)评定药物不良反应,根据卡氏功能量表(KPS)进行生活质量评估。结果 HAMD和HAMA评分显示,与治疗前相比,度洛西汀组治疗1wk末起评分有显著下降(P<0.05),氟西汀组治疗2wk末起评分有显著下降(P<0.05),2组评分同期比较1、2 wk末均有显著差异(P<0.05);2组在6wk末疗效、生活质量和不良反应方面均无显著差异(P>0.05)。结论度洛西汀治疗癌症抑郁疗效与氟西汀相当,但起效更快,耐受性好。AIM To evaluate the effectiveness and safety of duloxetine for the treatment of cancer patients with depression.METHODS Sixty cancer patients with depression were assigned into duloxetine and fluoxetine groups（n=30,each） in a open,randomized,prospective trial,and were treated for 6 wk. Clinical effectiveness,quality of life and adverse reactions were assessed with the Hamilton Depression Scale （HAMD）,Hamilton Anxiety Scale（HAMA）,Karnofsky Scale（KPS）,and Treatment Emergent Symptom Scale（TESS）,respectively.RESULTS Compared with pre-treatment,the scores of HAMD and HAMA in duloxetine group decreased significantly since 1-week treatment,and those scores in fluoxetine group decreased significantly since 2-week treatment（P0.05）.There were significant difference in the scores of HAMD and HAMA between the two groups at the end of 1 wk and 2 wk（P0.05）.No differences were observed in efficiency,improvement of quality of life and adverse reactions between the two groups at the end of 6 wk（P0.05）.CONCLUSION Duloxetine is a safe,effective and rapidly acting antidepressant in cancer patients with depression.

关 键 词：度洛西汀 氟西汀 癌 抑郁症 

分 类 号：R971.43[医药卫生—药品] R969.4[医药卫生—药学]